Brenda W Cooper
Overview
Explore the profile of Brenda W Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woost P, William B, Cooper B, Ueda Oshima M, Otegbeye F, De Lima M, et al.
Cytometry B Clin Cytom
. 2024 Feb;
106(1):11-24.
PMID: 38345160
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic...
2.
Metheny L, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, et al.
Blood Adv
. 2024 Jan;
8(6):1384-1391.
PMID: 38170741
The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) is an anti-CD22 monoclonal antibody bound to calicheamicin,...
3.
Pratz K, Cherry M, Altman J, Cooper B, Podoltsev N, Cruz J, et al.
J Clin Oncol
. 2023 Jun;
41(26):4236-4246.
PMID: 37379495
Purpose: Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory -mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction...
4.
Ali N, Sharma A, de Rezende A, Otegbeye F, Latif B, Kerbauy M, et al.
Transplant Cell Ther
. 2022 Apr;
28(7):370.e1-370.e10.
PMID: 35421620
Reduced-intensity conditioning (RIC) regimens frequently provide insufficient disease control in patients with high-risk hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated intensification of fludarabine/busulfan (Flu/Bu) RIC with...
5.
Luger S, Wang V, Rowe J, Litzow M, Paietta E, Ketterling R, et al.
Leuk Res
. 2021 Nov;
111:106736.
PMID: 34773794
Purpose: Despite the achievement of complete remission with chemotherapy in patients with acute myeloid leukemia (AML), relapse is common and the majority of patients will die of their disease. Patients...
6.
Ahmed N, Li L, Rojas P, Covut F, Reese-Koc J, Kolk M, et al.
Bone Marrow Transplant
. 2021 Jan;
56(6):1458-1461.
PMID: 33514923
No abstract available.
7.
Wang J, de Lima M, Cooper B, Boughan K, Metheny L, Otegbeye F, et al.
Leuk Lymphoma
. 2021 Jan;
62(6):1450-1457.
PMID: 33461376
The role of filgrastim during acute myeloid leukemia (AML) induction therapy remains controversial. At our institution, newly diagnosed AML patients from 2003 through 2019 were retrospectively evaluated. Patients were stratified...
8.
Tomlinson B, Gallogly M, Kane D, Metheny L, Lazarus H, William B, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Feb;
20(4):226-233.e1.
PMID: 32085993
Background: Midostaurin, a multikinase inhibitor, is approved for treatment of FLT3-mutant acute myeloid leukemia (AML). A phase I study established that midostaurin 75 mg orally twice daily for 14 days...
9.
Yeshurun M, Weisdorf D, Rowe J, Tallman M, Zhang M, Wang H, et al.
Blood Adv
. 2019 Feb;
3(4):670-680.
PMID: 30808685
Allogeneic hematopoietic cell transplant is a potential curative therapy for acute lymphoblastic leukemia (ALL). Delineating the graft-versus-leukemia (GVL) effect as a function of graft-versus-host disease (GVHD) offers the potential to...
10.
Covut F, Gupta D, Pinto R, Dambrosio N, Jurdi N, Meyerson H, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Dec;
19(2):73-82.
PMID: 30528848
Introduction: Induction chemotherapy with cytarabine and an anthracycline (7+3) remains the standard of care for acute myeloid leukemia (AML). Patients And Methods: We retrospectively analyzed 183 newly diagnosed AML patients...